Page 9 of 40: studies 81 to 90 of 391, newest first. Back to the end-of-life distress overview
The American journal of hospice & palliative care July 19, 2023
Mindfulness on Symptom Control and Quality of Life in Patients in Palliative Care: A Systematic Review.
BMC Palliative Care April 10, 2023 Franziska Lautwein, Manuela Schallenburger, Alexandra Scherg et al. 9 citations
BACKGROUND: Palliative care teams work under challenging conditions in a sensitive setting with difficult tasks. The multi-professional team can play an important role. Mindfulness and compassion-based practices are used to build resilience. Our aim was to examine (1) feasibility and acceptability, (2) satisfaction and impact, and (3) opportunities and limitations of a mindfulness course....
AJOB Neuroscience April 3, 2023 Christopher Poppe, Manuel Trachsel
Aday, J. S., C. C. Davoli, and E. K. Bloesch. 2019. 2018: A watershed year for psychedelic science. Drug Science, Policy and Law 5. doi:10.1177/2050324519872284. Chapman, M., J. Philip, and P. Komesaroff. 2019. Towards an ecology of dementia: A manifesto. Journal of Bioethical Inquiry 16 (2):209–16. doi:10.1007/s11673-01909910-8. Cunningham, C., S. Macfarlane, and H. Brodaty. 2019. Language...
Cancers January 7, 2023 Joshua D. Rosenblat, Froukje E. deVries, Zoe Doyle et al. 49 citations
Antidepressants require several weeks for the onset of action, a lag time that may exceed life expectancy in palliative care. Ketamine has demonstrated rapid antidepressant effects, but has been minimally studied in cancer and palliative care populations. Herein, the objective was to determine the feasibility, safety, tolerability and preliminary efficacy of intranasal racemic ketamine for...
Current geriatrics reports 2023 Emily Whinkin, Moira Opalka, Conor Watters et al. 26 citations
This review article summarizes clinically and socially relevant developments over the past five years in the therapeutic use of the classical tryptamine psychedelic substance psilocybin, with respect to the common challenges faced by palliative care patients and their care teams. Psilocybin is available in whole fungal and isolated forms but is not yet approved for therapeutic use in the United...
Oxford University Press eBooks December 1, 2022 Stephen Ross, Anthony P. Bossis
Abstract Following a decades-long hiatus and building on an innovative research model first developed from the 1960s to 1970s utilizing psychedelic therapeutics to alleviate the marked psychic distress in end-of-life cancer patients, major academic centers are resuming contemporary clinical research into the safety and efficacy of psilocybin and other serotonergic psychedelics delivered in...
Cochrane Database of Systematic Reviews November 21, 2022 Sivan Schipper, Kabir Nigam, Vanessa Piechotta et al. 4 citations
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of psychedelic/entactogen‐assisted therapy compared to placebo or active comparators (e.g. antidepressants) for treatment of anxiety, depression, and existential distress in adult palliative care.
Canadian Family Physician November 1, 2022 Ryan Patchett-Marble, Sean O’sullivan, Sayali Tadwalkar et al. 13 citations
Psychedelic medicine is currently undergoing a renaissance, with interest in the medical use of these compounds exploding after decades of dormancy.[1][1] This has occurred primarily under the purview of medical researchers; however, recent legal precedents in Canada have allowed some access to
Neuropharmacology September 15, 2022 S Ross, M Agrawal, Roland R. Griffiths et al. 69 citations
Psychiatric and existential distress commonly occur in advanced cancer and other serious, life-threatening or end-of-life medical illnesses and are associated with poor medical and psychiatric outcomes. Currently available treatment modalities in this patient population, including medication and psychotherapy, are limited in effectiveness, especially regarding existential distress. The lack of...
Journal of Palliative Medicine August 1, 2022 William E Rosa, Zachary Sager, Megan Miller et al. 49 citations
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence supports PAT as a novel therapeutic approach that provides safe and effective treatment for people suffering from a variety of diagnoses, including treatment-resistant depression, substance use disorder, and post-traumatic stress disorder. Within...